Table 2.
Numbers of microparticles in participators of the studya.
| Immune phenotype of MPs | Healthy volunteers (n = 35) | Entire cohort of enrolled MetS patients (n = 101) | MetS patients without CHF (n = 47) | MetS patients with CHF (n = 54) |
|---|---|---|---|---|
| CD41a+ MPs (n/µL) | 23 (19–28) | 25 (16–33) | 23 (15–31) | 27 (19–36) |
| CD64+ MPs (n/µL) | 3.9 (3.5–4.6) | 4.2 (3.2–5.1) | 4.0 (3.4–4.8) | 4.3 (3.6–5.2) |
| CD62E+ MPs (n/µL) | 1.35 (0.95–1.68) | 1.03 (0.86–1.13)b | 1.05 (0.88–1.18) | 0.98 (0.89–1.12) |
| CD105E+ MPs (n/µL) | 2.32 (1.92–2.56) | 2.24 (1.85–2.41)b | 2.37 (1.92–2.68) | 2.09 (1.58–2.50) |
| CD144+ MPs (n/µL) | 0.29 (0.22–0.36) | 0.33 (0.24–0.39) | 0.30 (0.22–0.37) | 0.35 (0.21–0.40) |
| CD144+/CD31+ MPs (n/µL) | 0.87 (0.27–1.25) | 0.92 (0.36–1.32) | 0.89 (0.32–1.29) | 0.93 (0.41–1.33) |
| Annexin V+ MPs (n/µL) | 4655 (3724–6237) | 5495 (3988–6957) | 5114 (3695–6547) | 5844 (4213–7167) |
| CD144+/annexin V+ MPs (n/µL) | 0.95 (0.11–1.78) | 1.15 (0.13–2.41) | 1.08 (0.13–2.39) | 1.17 (0.15–2.55) |
| CD144+/CD31+/annexin V+ MPs (n/µL) | 0.82 (0.27–1.55) | 1.01 (0.39–1.70) | 0.94 (0.38–1.52) | 1.12 (0.40–1.67) |
| CD31+/annexin V+ MPs (n/µL) | 0.154 (0.03–0.21) | 0.316 (0.261–0.374)b | 0.285 (0.253–0.318) | 0.355 (0.294–0.382)c |
| CD62E+ to CD31+/annexin V+ ratio, unit | 8.77 (7.95–9.18) | 3.26 (3.23–3.30)b | 3.68 (3.47–3.81) | 2.76 (2.42–3.04)c |
| CD105E+ to CD31+/annexin V+ ratio, unit | 15.1 (8.59–23.4) | 7.07 (4.85–10.90) | 8.31 (6.02–10.65) | 5.89 (4.11–7.67) |
IQR: inter quartile range; MPS: microparticles; MetS: metabolic syndrome; CHF: chronic heart failure;
aData are presented as median and 25–75% IQR. P-value is a comparison of mean or median variables between both cohorts (ANOVA test).
bSignificant difference between healthy subjects and entire cohort of enrolled patients.
cSignificant difference between MetS subjects with and without CHF.